1. The hallmarks of cancer;Hanahan;Cell,2000
2. the emerging pharmacogenomics revolution;Price Waterhouse Coopers, Global Technology Center, Health Research Institute,2005
3. Dose escalation trial designs based on a molecularly targeted endpoint;Hunsberger;Statistics Med,2005
4. Role of tyrosine kinase inhibitors in cancer therapy;Arora;J Pharmacol Exp Ther,2005
5. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter;Davies;J Pharmacy Pharm Sci,2004